All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-04-06T15:51:59.000Z

FDA grants ALPN-101 an Orphan Drug Designation for the prevention and treatment of acute GvHD

Apr 6, 2020
Share:

On March 18, 2020, the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for ALPN-101 for the prevention and treatment of acute graft-versus-host disease (aGvHD).1

ALPN-101 is a first-in-class Fc fusion protein of a human inducible T-cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™). The drug targets inflammatory process by simultaneous inhibition of the CD28 and ICOS signaling pathways, which are involved in T-cell activation. Results in preclinical models of GvHD, and other autoimmune and inflammatory diseases, such as inflammatory arthritis, and multiple sclerosis, revealed improved efficacy of dual CD28-ICOS blockade with ALPN-101 vs single pathway blockade.2

A phase I study (NCT03748836) of ALPN-101 in healthy volunteers completed enrolment in October 2019. The initial data were presented at the American Society of Hematology annual meeting in December 2019, with more data expected in 2020. A phase I/IIb Balance study (NCT04227938) investigating ALPN-101 in patients with steroid-refractory/resistant aGvHD is currently recruiting.

  1. Alpine Immune Sciences. Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease. https://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-alpn-101-receives-fda-orphan-drug. Published March 18, 2020. Accessed April 6, 2020

  2. Dillon S, Lewis K, Evans L. et al. Alpn-101, a Dual ICOS/CD28 Antagonist, Demonstrates Potent and Dose-Dependent Suppression of Graft Vs. Host Disease (GvHD) in a Human/NSG Mouse Xenograft Model, with Activity Superior to CD28 or ICOS Single Pathway Antagonists. Biol Blood Marrow Tr. 2019; 25(3):S290– DOI:10.1016/j.bbmt.2018.12.666

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox